Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Retinopathy (DR) Clear all
Completed No phase listed Observational

Computer Detection of Diabetic Retinopathy Compared to Clinical Examination

NCT01625598
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Photography of the retina, Retinal photography
Procedure
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Mesa, Arizona • Phoenix, Arizona • Cedar Rapids, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting No phase listed Observational

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

NCT07216677
View directory record Official record
Conditions
Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions
Chronic Disease Intervention CDI
Other
Lead sponsor
Interstat LLC
Other
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

NCT03403686
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
blood draw
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 98 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy

NCT05296447
View directory record Official record
Conditions
Diabetic Retinopathy, DR
Interventions
No Intervention
Other
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional

Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center

NCT07519707
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Macular Edema (ME)
Interventions
Animated Videos
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated No phase listed Observational

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

NCT02875704
View directory record Official record
Conditions
Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions
Anterior Chamber (AC) Tap
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

NCT06721351
View directory record Official record
Conditions
Diabetic Retinopathy (DR)
Interventions
Diabetic Retinopathy screening Point of Care Artificial Intelligence
Diagnostic Test
Lead sponsor
Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health
Other
Eligibility
22 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Chula Vista, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

ACCESS: AI for pediatriC diabetiC Eye examS Study

NCT05131451
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NCT04567550
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Enrolling by invitation Phase 4 Interventional

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT07456826
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions
Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
Drug · Procedure
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Metabolic Mapping to Measure Retinal Metabolism

NCT00385333
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
Interventions
Feasibility Study - Imaging System
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional

Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images

NCT06241664
View directory record Official record
Conditions
Diabetic Retinopathy, DR, Diabetic Mellitus
Interventions
AEYE-DS Software
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

NCT04919499
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 765128, Sham comparator
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

NCT06593405
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
occupational therapy interventions for low vision care
Combination Product
Lead sponsor
MCPHS University
Other
Eligibility
50 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

NCT05607810
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional

Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)

NCT07296952
View directory record Official record
Conditions
Diabetic Retinopathy (DR)
Interventions
PRONTO-EYE
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of AI Program 'DRISTi' as a Screening Tool

NCT07222293
View directory record Official record
Conditions
Diabetic Retinopathy (DR)
Interventions
Fundus Image Grading
Diagnostic Test
Lead sponsor
Artelus AI
Industry
Eligibility
21 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Oxford, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 3 Interventional

Fenofibrate for Prevention of DR Worsening

NCT04661358
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 80 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
66
States / cities
Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

NCT07105228
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
290,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 20, 2026, 6:42 PM EDT